A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome

Guillermo Garcia-Manero, Gary Gartenberg, David P. Steensma, Martin R. Schipperus, Dimitri A. Breems, Raquel de Paz, David Valcárcel, Britte Kranenburg, Manjula Reddy, Rami S. Komrokji

    Research output: Contribution to journalArticleResearchpeer-review

    19 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome'. Together they form a unique fingerprint.

    Nursing and Health Professions

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science

    Chemistry

    Biochemistry, Genetics and Molecular Biology